Mondi hosts first-of-its-kind round table to tackle used paper bags from construction

Highlights • Robust financial performance in a challenging environment ◦ Underlying EBITDA of €738 million with margin of 21.4% ◦ Profit before tax of €466 million ◦ Basic underlying earnings of 73.0 euro cents per share ◦ Cash generated from operations of €602 million ◦ Return on capital employed of 17.1% ◦ Strong balance sheet with 1.4 times net debt to 12-month trailing underlying EBITDA at 30 June 2020

Neenah, Inc. announced a versatile paper-based medical packaging capable of withstanding all three widely used sterilization processes, including radiation, autoclave, and ethylene oxide. This innovative product allows customers to serve multiple markets and explore new opportunities by providing a unique alternative to polymer-based or kraft medical packaging traditionally used for nasal swabs, syringes, bandages, and other single-use applications. "By adding a radiation-resistant product to our medical packaging lineup, Neenah continues to lead the industry in offering the most advanced paper-based options available. We are thrilled to introduce a versatile paper-based medical packaging that is durable, dependable, and value-driven," says Valerie Henderson, Medical Packaging Product Marketing Manager, Neenah Industrial Solutions. Single-use medical devices are gaining popularity as they help lower costs, increase efficiency, and reduce the spread of infection. Gamma radiation is becoming a more commonly used form of sterilization technology for these devices as it quickly kills germs that can cause disease and neutralizes other harmful organisms. It is essential to the radiation sterilization process that the packaging has breathable barrier properties, excellent conformability, printability, and the ability to withstand radiation exposure to prevent risks to patients.

Pharmaceutical product packaging accounts for a large part of manufacturers’ Scope 3 emissions, which consider, for example raw material production, manufacturing, and end-of-life disposal. According to Metsä Board studies, fresh fibre paperboard can notably reduce the carbon footprint of pharmaceutical packaging by optimising the paperboard in use. Assessments* conducted by Metsä Board demonstrate the significant carbon footprint reductions that pharmaceutical manufacturers can achieve by switching from commonly used grades to Metsä Board fresh fibre paperboards. The lower carbon footprint of Metsä Board’s folding boxboards, compared to the above mentioned boards, is due to the use of fossil free energy in their production and their lighter weight. However, despite the lighter weight, Metsä Board’s folding boxboards still retain the durability and functional properties of traditional heavier grades.